Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 47, Issue 1, 1998, Pages 31-38

  Crowne, E C ^b   Samra, J S ^b   Cheetham, T ^b   Watts, A ^b   Holly, J M P ^b   Dunger, D B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; ISOPHANE INSULIN; OCTREOTIDE; PLACEBO; RECOMBINANT SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE RELEASE; HORMONE DETERMINATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN SENSITIVITY; INSULIN TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031951745     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90189-5     Document Type: Article

References (52)

1. Bolli GB, Gerich JE: The "dawn phenomenon" - A common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 310:746-750, 1984
2. Perriello G, De Feo P, Torlone E, et al: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52-59, 1990
3. Fowelin J, Attval S, von Schenck H, et al: Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34:500-506, 1991
4. Fowelin J, Attval S, von Schenck H, et al: Characterization of the insulin-antagonistic effect of growth hormone in insulin-dependent diabetes mellitus. Diabet Med 12:990-996, 1995
5. Beaufrere B, Beylot M, Metz C, et al: Dawn phenomenon in type 1 (insulin-dependent) diabetic adolescents. Influence of nocturnal growth hormone secretion. Diabetologia 31:607-611, 1988
6. Edge JA, Harris DA, Phillips PE, et al: Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents. Diabetes Care 16:1011-1018, 1993
7. Pal BR, Philips PE, Matthews DR, et al: Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with insulin-dependent diabetes mellitus. Diabetologia 35:542-549, 1992
8. Holly JMP, Biddlecombe RA, Dunger DB, et al: Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin? Clin Endocrinol (Oxf) 29:667-675, 1988
9. Cheetham TD, Jones J, Taylor AM, et al: The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:678-681, 1993
10. Cheetham TD, Clayton KL, Taylor AM, et al: The effects of recombinant human insulin-like growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol (Oxf) 40:515-522, 1994
11. Dimitriadis G, Parry-Billings M, Piva T, et al: Effects of insulin like growth factor I on the rates of glucose transport and utilisation in rat skeletal muscle in vitro. Biochem J 285:269-274, 1992
12. Boulware SD, Tamborlane WV, Matthews LS, et al: Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 262:E130-E133, 1992
13. Turkalj I, Keller U, Ninnis R, et al: Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75:1186-1191, 1992
14. Laager R, Ninnis R, Keller U: Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 92:1903-1909, 1993
15. Hussain MA, Schmitz O, Mengel A, et al: Insulin-like growth factor-I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1993
16. Matthews DR, Edge JA, Dunger DB: An unbiased glucose clamp method using a variable insulin function: Its application in adolescents. Diabet Med 7:246-251, 1990
17. Castillo MJ, Scheen AJ, Letiexhe MR, et al: How to measure insulin clearance. Diabetes Metab Rev 10:119-150, 1993
18. Edge JA, Dunger DB, Matthews DR, et al: Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1362, 1990
19. Edge JA, Matthews DR, Dunger DB: The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics. Clin Endocrinol (Oxf) 33:729-737, 1990
20. Amiel SA, Sherwin RS, Simonson DC, et al: Impaired insulin action in puberty. A contributing factor to poor glycaemic control in adolescents with diabetes. N Engl J Med 315:215-219, 1986
21. Campbell PJ, Bolli GB, Cryer PE, et al: Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 312:1473-1479, 1985
22. Arslanian S, Ohki Y, Becker DJ, et al: The dawn phenomenon: Comparison between normal and insulin-dependent diabetic adolescents. Pediatr Res 31:203-206, 1992
23. Brennan JR, Gebhart SS, Blackard WG: Pump-induced insulin aggregation. A problem with the Biostator. Diabetes 34:353-359, 1985
24. Guler HP, Schmid C, Zapf J, et al: Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Nat Acad Sci USA 86:2868-2872, 1987
25. Keller S, Schmid C, Zapf J, et al: Inhibition of insulin degradation by insulin-like growth factors I and II in human hepatoma (HepG2) cells. Acta Endocrinol (Copenh) 121:279-285, 1989
26. Kahn CR, Megyesi K, Roth J: Nonsuppressible insulin-like activity of human serum. A potent inhibitor of insulin degradation. J Clin Invest 57:526-529, 1976
27. D'Ercole AJ, Decedue CJ, Furlanetto RW, et al: Evidence that somatomedin-C is degraded by the kidney and inhibits insulin degradation. Endocrinology 101:577-586, 1977
28. Ipp E, Sinai Y, Bar-Oz B, et al: Somatostatin impairs clearance of exogenous insulin in humans. Diabetes 36:673-677, 1987
29. Wildenhoff KE: The influence of diabetic regulation on the diurnal variation in blood and the urinary excretion of ketone bodies. Studies in newly diagnosed diabetics. Acta Med Scand 198:127-133, 1975
30. Aarson RSR, Bruining GJ, Grose WFA, et al: Long-acting somatostatin analogue (Sandostatin) reduces late-night insulinopenic ketogenesis in diabetic teenagers. Acta Endocrinol (Copenh) 116:45-53, 1987 (suppl 286)
31. Keller U, Schnell H, Girard J, et al: Effect of physiological elevation of plasma growth hormone levels on ketone body kinetics and lipolysis in normal and acutely insulin-deficient man. Diabetologia 26:103-108, 1984
32. Gerich JE, Lorenzi M, Bier DM, et al: Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. J Clin Invest 57:875-884, 1976
33. Moller N, Jorgensen JOL, Schmitz O, et al: Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 258:E86-E91, 1990
34. Livingston N, Pollare T, Lithell H, et al: Characterisation of insulin-like growth factor I receptor in skeletal muscles of normal and insulin resistant subjects. Diabetologia 31:871-877, 1988
35. Caro JF, Poulos J, Ittoop O, et al: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81:976-981, 1988
36. Zapf J, Schoenle E, Waldvogel M, et al: The effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: Further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 113:605-609, 1981
37. Sinha MK, Buchanan C, Leggett N, et al: Mechanism of IGF-I-stimulated glucose transport in human adipocytes. Demonstration of specific IGF-I receptors not involved in stimulation of glucose transport. Diabetes 38:1217-1225, 1989
38. Poggi C, Le Marchand Brustel Y, Zapf J, et al: Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: Comparison with insulin. Endocrinology 105:723-730, 1979
39. Bolinder J, Lindblad A, Engfeldt P, et al: Studies of acute effects of insulin-like growth factors I and II in human fat cells. J Clin Endocrinol Metab 65:732-737, 1987
40. King GL, Kahn CR, Rechler MM, et al: Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor. J Clin Invest 66:130-140, 1980
41. Zapf J, Hauri C, Waldvogel M, et al: Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77:1768-1775, 1986
42. Guler HP, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor-I in healthy adults. N Engl J Med 317:137-140, 1987
43. Giacca A, Gupta R, Efendic S, et al: Differential effects of IGF-I and insulin on glucoregulation and fat metabolism in depancreatized dogs. Diabetes 39:340-347, 1990
44. Zapf J, Schoenle E, Froesch ER: Insulin-like growth factors I and II: Some biological actions and receptor binding characteristics of two purified constituents of non-suppressible insulin-like activity of human serum. Eur J Biochem 87:285-296, 1978
45. Wasserman DH, Lickley HL, Vranic M: Role of beta-adrenergic mechanisms during exercise in poorly controlled diabetes. J Appl Physiol 59:1282-1289, 1985
46. Gray DE, Lickley HL, Vranic M: Physiologic effects of epinephrine on glucose turnover and plasma free fatty acid concentrations mediated independently of glucagon. Diabetes 29:600-608, 1980
47. Beylot M, Picard S, Chambrier C, et al: Effect of physiological concentrations of insulin and glucagon on the relationship between nonesterified fatty acid availability and ketone body production in humans. Metabolism 40:1138-1146, 1991
48. Batch JA, Baxter RC, Werther G: Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab 73:964-968, 1991
49. Cotterill AM, Daly F, Holly JMP, et al: The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: Possible contribution of insulin-like growth factor binding protein-1. Clin Endocrinol (Oxf) 43:567-574, 1995
50. Cheetham TD, Taylor A, Holly JM, et al: The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 142:367-374, 1994
51. Thraikill K, Quattrin T, Baker L, et al: Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: Effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 82:1181-1187, 1997
52. Dunger DB, Cheetham TD, Crowne EC: Insulin-like growth factors and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 44:1-6, 1995 (suppl 4)